Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, multi-center, multi-national, randomized withdrawal study to evaluate the safety and efficacy of BMS-188667 [abatacept] in children and adolescents with active polyarticular juvenile rheumatoid arthritis.

Next Previous
X
Search
Trial Profile

A phase III, multi-center, multi-national, randomized withdrawal study to evaluate the safety and efficacy of BMS-188667 [abatacept] in children and adolescents with active polyarticular juvenile rheumatoid arthritis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms AWAKEN; JIA-1
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 04 Jun 2022 Results (n=347) of an analysis assessing predictors of clinical response to abatacept in children with polyarticular juvenile idiopathic arthritis; using data from two phase 3 clinical studies: JIA-1 (2-17years; SC administration) and JIA-2 (6-17years; IV administration) presented at the 23rd Annual Congress of the European League Against Rheumatism
    • 15 Jan 2021 Results assessing the relationship between infection risk and abatacept exposure levels in patients with polyarticular-course juvenile idiopathic arthritis (pJIA) following treatment with subcutaneous and intravenous abatacept published in The Journal of Rheumatology
    • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top